Introduction
============

Contemporary genome-wide association studies (GWASs) test common single-nucleotide polymorphisms (SNPs) for association with disease risk. The underlying biological model is that the causal mutation is in linkage disequilibrium (LD) with tagging SNPs on the genotyping array.^[@bib1]^ If the causal mutation is also common, then it likely resides in close proximity to the disease-associated SNP. To fine map the strongest signal of association, it is necessary to perform dense genotyping in large patient collections, followed by stepwise conditional regression and haplotype analysis.^[@bib2]^ Genome-wide imputation from a reference panel, such as HapMap, facilitates this process by providing high-density coverage of common alleles across a locus of interest.^[@bib3]^

Rheumatoid arthritis (RA) is a common autoimmune disease of unclear etiology. Family studies estimate that \>50% of the variance in disease risk is genetic.^[@bib4]^ To date, \>20 risk loci have been identified conclusively at *P*\<5 × 10^−8^.^[@bib5],\ [@bib6]^ In an initial RA GWAS meta-analysis of 15 855 case--control samples, with replication in an additional 19 915 independent samples, we found strong but not conclusive evidence that a common SNP near *TAGAP* is associated with risk of RA (rs394581, *P*~GWAS~=5.6 × 10^−4^, *P*~overall~=3.8 × 10^−7^ in all 35 770 case--control samples combined).^[@bib7]^ This GWAS meta-analysis did not include complete imputation of all CEU HapMap SNPs, but rather included only 336 721 SNPs genotyped on the Affymetrix 500K platform (Affymetrix, Santa Clara, CA, USA) passing genotype quality control filters. In a follow-up GWAS meta-analysis of 5539 autoantibody-positive RA cases and 20 269 controls, we imputed 2.56 million SNPs from CEU HapMap and found continued evidence of association at the previous *TAGAP* RA risk SNP (rs394581, *P*~GWAS~=7.7 × 10^−4^).^[@bib6]^ However, we also found suggestive evidence for additional risk alleles at the *TAGAP* locus, including an allele associated with risk of celiac disease and type I diabetes (TID).^[@bib8],\ [@bib9]^

The purpose of the current study is to refine the signal of association at the *TAGAP* locus using our second GWAS meta-analysis with genome-wide imputation. Our results show that an imputed SNP at the *TAGAP* locus provides a much stronger signal of association than the previously published SNP in RA.

Results and discussion
======================

The initial goals of this study were to use genome-wide imputation and conditional analysis to determine if any of the known RA risk alleles had either (1) a better signal of association or (2) an independent, second signal of association in the associated risk locus. We included those RA risk loci with conclusive (*P*\<5 × 10^−8^) and highly suggestive (*P*\<10^−6^ with independent replication at *P*\<0.01) association with risk of RA.

Our GWAS meta-analysis was conducted using the six case--control collections shown in [Table 1](#tbl1){ref-type="table"}. Within each collection, we first filtered SNPs and individuals, and then ran Eigenstrat^[@bib10]^ on genotyped SNPs to calculate principal components, as previously described.^[@bib6]^ We used filtered SNPs to impute 2.56 million SNPs present at \>1% allele frequency in CEU HapMap.^[@bib3]^ GWAS association analyses were performed using logistic regression (SNPTEST and R), incorporating the top five principal components as covariates to control for population stratification. We combined the results of the GWAS for each data set by weighting the logistic regression estimates (beta values) by the inverse variance of each data set.^[@bib11]^ In our final analysis of 5 500 RA cases and 22 621 controls (all of European ancestry) with genotype data at 2.56 million SNPs, we found no evidence of systemic bias (*λ*~GC~=1.01). In comparison with the published GWAS by Stahl *et al.*,^[@bib6]^ here we added 2352 additional shared controls because we incorporated PC\'s into the GWAS to correct for stratification. In doing so, we removed 39 RA cases because they were determined to be genetic outliers by PC\'s in the expanded data set.

To refine the signal of association at each RA risk locus, we conditioned on the previously described SNP genotype to look for additional statistical evidence of association at other nearby SNPs. For each of the known RA risk loci, we assessed association statistics, both before and after conditional analysis, of SNPs within a 1-Megabase (Mb) region centered on the known RA risk allele. In our analysis conditional on the previously associated SNP, the *TAGAP* locus had a clear signal that was different than the previously reported SNP (Supplementary Table 1). The *TNFAIP3*, *CCL21*, *CTLA4-CD28* and *ANKRD55-IL6ST* loci showed evidence of independent, second signals of association, consistent with previous reports.^[@bib6],\ [@bib7],\ [@bib12]^ No other loci showed strong evidence for association after analysis conditional on the previously associated RA SNP (conditional *P*\<10^−4^). Because of these findings, we focused solely on refining the signal of association at the *TAGAP* locus. We note, however, that our study design has limited power to detect independent rare alleles or common alleles of more modest effect.

In unconditional analysis, the new *TAGAP* SNP, rs212389, reached a conservative level of genome-wide significance in our GWAS meta-analysis (*P*=3.9 × 10^−8^, odds ratio=0.87). As shown in [Figure 1a](#fig1){ref-type="fig"}, the new *TAGAP* SNP, rs212389, was five orders of magnitude more significant than the previously reported *TAGAP* SNP (rs394581). These two SNPs are located only 7.3 kb apart and are in LD with one another (*r*^2^=0.59 and *D*′=0.92). Importantly, the new *TAGAP* SNP had not been genotyped directly in any of the six collections.

Conditional analysis revealed that the new *TAGAP* SNP, rs212389, better explains the association at this locus than the previously associated RA *TAGAP* SNP. After conditioning on the previously reported *TAGAP* SNP (rs394581), the new *TAGAP* SNP (rs212389) remained highly significant (*P*=2.2 × 10^−6^; [Figure 1b](#fig1){ref-type="fig"}). In contrast, conditioning on the new *TAGAP* SNP abrogated any remaining signal across the entire 1-Mb region, including any signal at the previously reported *TAGAP* SNP (rs394581; *P*=0.07; [Figure 1c](#fig1){ref-type="fig"}).

The same *TAGAP* locus is associated with risk of celiac disease and TID.^[@bib8],\ [@bib9]^ The celiac/TID risk allele appears different than the RA risk allele, as the new RA SNP demonstrates evidence of association even after analysis conditioning on the celiac/TID SNP, rs1738074 (*P*=1.7 × 10^−4^). These results are consistent with the patterns of LD between the pairs of SNPs: the celiac/TID SNP, rs1738074, has *r*^2^=0.32 with the new RA risk SNP, rs212389, and *r*^2^=0.35 with the previously reported RA risk SNP, rs394581.

As the new *TAGAP* SNP was imputed in all six GWAS collections, we wanted to ensure that the signal of association was not driven by any one GWAS collection, and that the association was not an artifact of imputation. As shown in [Figure 2](#fig2){ref-type="fig"}, the new *TAGAP* SNP (rs212389) demonstrated a signal of association in all six GWAS collections. For the new *TAGAP* SNP, the imputation scores were higher for those samples genotyped using the Illumina platform (Illumina, San Diego, CA, USA; Epidemiological Investigation of Rheumatoid Arthritis (EIRA), North American Rheumatoid Arthritis Consortium (NARAC) 1 & 2, and Canada; Supplementary Table 2).

To further fine map the signal of association, we used our GWAS meta-analysis to construct haplotypes generated by these three SNPs (new RA SNP, previous RA SNP and celiac/TID SNP). As the imputation scores were higher for those samples genotyped using the Illumina platform, we analyzed only on those 3501 RA cases and 10 433 controls genotyped on Illumina (see [Table 1](#tbl1){ref-type="table"}). As shown in [Figure 3](#fig3){ref-type="fig"}, our haplotype analysis indicated that the best genetic model is one in which the haplotype tagged by the G allele of rs212389 (new RA) and the T allele of rs1738074 (celiac/TID SNP) confers protection from RA (*P*=1.1 × 10^−6^). A similar but more significant result is obtained when we use all six GWAS collections in our analysis (*P*=1.8 × 10^−8^).

To test whether risk is best explained by the rs212389-G/rs1738074-T common haplotype, rather than either allele alone, we performed an analysis in which we compared three risk models: G allele of rs212389 (new RA), T allele of rs1738074 (celiac/TID) and rs212389-G/rs1738074-T common haplotype. Consistent with our other analyses, we found that the rs212389-G/rs1738074-T model was significantly better than either model, which included only a single SNP (*P*=0.01; Supplementary Table 3). Although this analysis suggests that the causal allele resides on the rs212389-G/rs1738074-T, additional genotyping in large multi-ethnic sample collections will be required to formally identify the best genetic model at the *TAGAP* locus.

Under a model in which the causal allele is common and tagged by the common G-rs212389/T-rs1738074 haplotype, then the causal allele should be catalogued within the 1000 Genomes Project, as this haplotype is common (present in ∼31% of control chromosomes). We used phased 1000 Genomes data to identify all variants in high LD (*r*^2^\>0.80) with the new risk haplotype (Supplementary Table 4). At this LD threshold, we identified only 10 potential causal variants. However, none of these variants were within the protein-coding sequence of *TAGAP* or other neighboring genes, and none disrupted an obvious non-coding functional motif (for example, transcription factor binding site).

Although *TAGAP* is the most promising biological candidate gene, four other genes map to the region of LD: *EZR*, *OSTCL/LOC202459, RSPH3* and *FNDC1* ([Figure 1](#fig1){ref-type="fig"}). *TAGAP* gene is expressed at high levels in the immune system, including B- and T-lymphocyte cells, dendritic cells, natural killer cells and monocytes. The protein product is predicted to function as a Rho GTPase-activating protein. Otherwise, little is known about the function of *TAGAP* in the immune system.

There are several important limitations of our study. First, we did not genotype the new RA-associated SNP in any samples. The imputation quality score (Supplementary 2) and the consistency of the effect across the different cohorts ([Figure 2](#fig2){ref-type="fig"}) provide strong evidence that the signal of association at the imputed SNP is not because of a technical artifact. Second, no re-sequencing was done to discover variants not present in either HapMap or 1000 Genomes data. Formally speaking, our results could be consistent with a genetic model in which multiple causal rare variants reside on the common G-rs212389/T-rs1738074 haplotype, rather than a single causal allele that resides on this haplotype. Third, our study is underpowered to detect independent alleles of modest effect, especially those that are of low allele frequency (for example, 1--5%). Last, we did not perform experiments to determine whether the new RA SNP (rs212389) or any variants from the 1000 Genomes data in LD with the common G-rs212389/T-rs1738074 haplotype are functional.

In conclusion, our study provides conclusive evidence that the *TAGAP* locus is associated with risk of RA. In doing so, we have refined the signal of association at the *TAGAP* locus either to rs212389 (new RA SNP) or to a haplotype tagged by the G allele of rs212389 (new RA SNP) and the T allele of rs1738074 (celiac/TID SNP). Comprehensive imputation was essential to refine this association, as the new SNP was not genotyped directly on either the Affymetrix or Illumina platforms.
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![*TAGAP* results from GWAS meta-analysis. (**a**) Results conditional only on the top five principal components (PCs). (**b**) Results conditional on previous RA SNP, rs394581 (in addition to five PCs). (**c**) Results conditional on new RA SNP, rs212389 (in addition to five PCs). In each plot, genotyped SNPs (diamonds) and imputed SNPs (circles) are shown across a 500-kb window, where the color of the symbol indicates LD (as measured by *r*^2^) to the new RA SNP (rs212389). Two genes, *TAGAP* and *RSPH3*, map within the recombination hotspots (shown in blue); three other genes map to the region (*EZR*, *OSTCL/LOC202459* and *FNDC1*).](gene20118f1){#fig1}

![*TAGAP* results for previous RA SNP (rs394581), new RA SNP (rs212389) and celiac/TID SNP (rs1738074), within each GWAS collection. In each plot, the point estimate of the odds ratio (OR) is shown, with 95% confidence intervals (CI). Genotyped SNPs are indicated by diamonds and imputed SNPs by circles. The meta-analysis of all six collections is indicated by the filled diamond at the bottom of the graph, where the edges of the diamond indicate the 95% CI. For the new RA SNP (rs212389), the OR is 0.87 (95% CI 0.83--0.91).](gene20118f2){#fig2}

![*TAGAP* results for haplotypes created by the celiac/TID SNP (rs1738074), previous RA SNP (rs394581) and new RA SNP (rs212389). Seven haplotypes are created by the three SNPs. The frequency of each haplotype from the control population is shown. The point estimate of the odds ratio (OR) and 95% confidence intervals (CI) are shown.](gene20118f3){#fig3}

###### Case--control samples for GWAS meta-analysis

                                *Case collection*                                              *Control collection*         *Geographical origin*    *Antibody status*  *Cases*   *Controls*   *Genotyping platform*
  ----------------------------- -------------------------------------------------------------- ---------------------------- ----------------------- ------------------- --------- ------------ -----------------------
  Meta-analysis                 Brigham Rheumatoid Arthritis Sequential Study (BRASS)          Shared controls              Boston, USA                  100% CCP+      478       1631         Affymetrix 6.0
                                Canada                                                         Canada and shared controls   Toronto, Canada              100% CCP+      589       1554         Illumina 370K
                                Epidemiological Investigation of Rheumatoid Arthritis (EIRA)   EIRA                         Sweden                       100% CCP+      1142      1072         Illumina 317K
  5500 cases, 22 621 controls   North American Rheumatoid Arthritis Consortium (NARAC) I       Shared controls              North America                100% CCP+      868       1194         Illumina 550K
                                NARAC III                                                      Shared controls              North America                100% CCP+      902       6613         Illumina 317K
                                Wellcome Trust Case Control Consortium (WTCCC)                 Shared controls from WTCCC   UK                       100% RF+ or CCP+   1521      10557        Affymetrix 500K

Abbreviations: CCP, cyclic citrullinated peptide; GWAS, genome-wide association study; RF, rheumatoid factor.

The characteristics of the six case--control collections used in the GWAS meta-analysis are shown.
